Department of Health and Human Services' logo Department of Health and Human Services

Public Health Service
Food and Drug Administration
Cincinnati District Office


6751 Steger Dr
Cincinnati, OH 46237-3097
Telephone: 513-679-2700
FAX: 513-679-2761

August 20, 1998

Elaine H. Parrish, President
EHP Products, Inc.
8 Kenton Furnace Dr
PO Box 1306
Ashland, KY 41105-1306

Ref. No. CIN-98-295

Dear Mrs Parrish:

This letter is in reference to your firm's marketing and distribution of the products Myristin Capsules, Myrist-Aid Capsules and Myristin-TF Topical Lotion. Claims made in the labeling for these products cause them to be drugs [section 201(g) of the Federal Food, Drug and Cosmetics Act (the Act)].

Cetyl Myristoleate labeling claims in the brochure titled "Cetyl Myristoleate Nature's Answer to Arthritis" by Dr Charles L. Cochran, include:

These products are "new drugs" (Section 201(p) of the Act) because they are not generally recognized as safe and effective for the claimed conditions and they have not been approved for these purposes (Section 505(a) of the Act).

These drugs are also misbranded [Section 502(f)(1) of the Act] because the labeling fails to bear adequate directions for use. The labeling is false and misleading because it suggests that the products are safe and effective for their intended uses when this has not been established [Section 502(a) of the Act].

We are also aware of additional printed material, and your Internet pages that include unsubstantiated claims and testimonials for your products for the prevention and cure of arthritis and other disease conditions. These claims fullher demonstrate the intended drug use of your products.

This letter is not intended to be an all-inclusive review of all labeling and products that your firm markets. It is your responsibility to ensure that all products marketed by your firm are in compliance with the Act and its implementing regulations. (This includes all labeling and promotional materials).

We request that you take prompt action to correct these violations. Failure to promptly correct violations may result in enforcement action being initiated by the Food and Drug Administration without further notice. The Federal Food, Drug and Cosmetic Act provides for the seizure of illegal products and for injunction against the manufacturer and/or distributor of illegal products.

Please notify this office in writing within fifteen (15) working days of receipt of this letter as to the specific steps you have taken to correct the stated violations, You should also include an explanation of each step being taken to identify and make corrections to assure that similar violations will not recur. If corrective action cannot be completed within 15 working days,

Please state the reason for the delay and the time within which the corrections will be completed.

Your reply should be sent to Lawrence E. Boyd, Compliance Officer, Food and Drug Administration, 6751 Steger Dr, Cincinnati, OH 45237-3097.

Carol A. Heppe
Acting District Director

This page was posted on August 20, 2006.

Links to Recommended Companies

  • Compare drug prices and save money at verified online pharmacies.
  • Evaluates the quality of dietary supplement and herbal products.
  • Discount prices, huge inventory, and superb customer service.
  • OnlyMyEmail: Award-winning anti-spam services.
  • 10 Types: Website design, development, and hosting with superb technical support.